New Grant Awarded to SPORE in Prostate Cancer
The Robert H. Lurie Comprehensive Cancer Center was awarded a new $11.3 million, five-year competitive grant from the National Cancer Institute (NCI) in August, 2015 for its continued leadership of a Specialized Programs of Research Excellence (SPORE) in prostate cancer; one of only eight in the country.
First funded in 2001 and refunded in 2009, the Prostate SPORE unites basic scientists, clinicians, pathologists, biostatisticians, bioinformaticians, and advocates to examine the basic biology of prostate cancer and to design and conduct innovative clinical trials that will offer entirely new approaches to the treatment of prostate cancer. The multi-center consortium provides an integrated scientific environment that leverages the expertise of its investigators to conduct four highly translational research projects. In addition, the SPORE grant funds the collection of well-annotated biospecimens through a biospecimen pathology core, a biostatistics and bioinformatics core facility, an administrative core plus Developmental Research (DRP) and a Career Enhancement (CEP) Programs.
LeadershipPrincipal Investigator: William Catalona, MD, Professor of Urology.
Co-PI: Walter Stadler, MD, Professor of Medicine (University of Chicago).
Prostate Cancer Clinical Trials at SPORE Sites